Clinical trial
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced…
NCT00151047 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00151047 |
|---|---|
| Title | Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer |
| Official title | Evaluation of Primary Chemotherapy With Docetaxel Plus Capecitabine in Selected Patients With Newly Diagnosed Localized or Locally Advanced Prostate Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Docetaxel |
| Enrollment | 15 |
| Start date | Mar 1, 2003 |
| Primary completion | Jan 1, 2005 |
| Completion | Oct 1, 2007 |
| First posted | Sep 8, 2005 |
| Last update posted | Jan 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: